Subscribe to:
POZ magazine E-newsletters
POZ Personals Sign In / Join
Username:
Password:
June 2009 Success
Kaletra to Norvir/Reyataz Switch Improves Fat, Glucose Metabolismdone
Higher HIV Levels Increase Lymphoma Riskdone
Tesamorelin for Lipodystrophy Approval Application Fileddone
Crystal Use Might Increase Lymphoma Riskdone
New Hope for HIV Eradicationdone
Apricitabine Trial Continues, With Changesdone
Liver Transplant in HBV/HIV Coinfected Patients Successfuldone
Repeat Pregnancies Likely With Only Condomsdone
Enzyme Related to Heart Disease No Higher in HIV-Positive Womendone
Early HIV Treatment Could Protect Against Brain Dysfunctiondone
B Cell Test Predicts Who Will Get Meningitisdone
HIVMA Advocates for Public Insurance Optiondone
Interleukin-10 Blunts HIV Infection and Disease Progressiondone
Preterm Delivery, Low Birth Weight Unlikely with Perinatal HIV Treatmentdone
New Ideas About Reaching HIV Sanctuaries in the Bodydone
HIV Infection and Diabetes Riskdone
Second-Line Treatment for PCP a Viable Alternativedone
Improving Survival From Non-Hodgkin’s Lymphomadone
High Percentage of U.S. Residents Receiving Late HIV Diagnosesdone
HIV and ARV Therapy Accelerate Bone Lossdone
May 2009 Success
Turning On Old Genes to Prevent HIVdone
HPV Greatly Increases HIV Infection in MSMdone
Lower-Dose ARVs to Be Tested in New Gates-Funded Programdone
Obama to Broaden, Expand PEPFAR to $51 Billion Over Six Yearsdone
Hep C and Heavy Drinking Tied to Bone Fracturesdone
Telaprevir Increases Hep C Treatment Responsedone
Journalist Files Libel Suit Against HIV Treatment Advocatedone
HPV Vaccine Is Active in MSMdone
Gardasil Blocks About Half of Cervical Lesionsdone
Study: HIV Not Becoming More Virulentdone
Interleukin-21 Tied to Control of Chronic Infections Like HIVdone
HIV Associated With Marked Declines in Lung Functiondone
Study Authors Say Treat HIV and OIs at Same Timedone
Is HIV Itself a Risk Factor for Heart Disease?done
Frequent False-Positive Drug Tests With Efavirenz Usersdone
Gingko May Lower Efavirenz Blood Levelsdone
Combivir Linked to Lipoatrophy in Small European Studydone
New California Budget Slashes $55.5 Million From AIDS Fundsdone
Kaletra Maintenance Monotherapy Holds Up Over 96 Weeksdone
Viral Load Tied to Kidney Functiondone
Is Marijuana as Effective as OTC and Prescription Drugs?done
April 2009 Success
New Drug May Boost HIV Treatment Effectivenessdone
Published Study Says Start HIV Treatment as Early as Possibledone
Shorter Duration Hep C Treatment May Be Possible for Somedone
Vitamin D Might Blunt Tenofovir-Associated Bone Problemsdone
HIV Treatment Alone Is Enough for Most Who Catch KS Earlydone
Kaletra Might Cause Heart Rhythm Disturbancesdone
Leptin Reduces Belly Fatdone
Scientists Discover How Herpes Viruses May Lead to Cancerdone
Another Study Recommends Earlier ARV Treatmentdone
Is Big Pharma Stifling AIDS Research?done
Possible Interaction Between Isentress and Intelence?done
GSK, Pfizer Team for Combined HIV Drug Companydone
BMS Launches Co-Pay Assistance Programdone
“Quad” HIV Pill Enters Phase II Studydone
Isentress’s Prevention Potentialdone
HIV Treatment May Offer Only Partial Heart Protectiondone
New Research Shows Why Antibodies Fail to Control HIVdone
Atripla Co-pay Program Announceddone
HIV Positive and Negative Have Equal Liver Transplant Survival Ratesdone
Aquamid a Safe and Effective Treatment for Facial Wastingdone
Prezista Levels in the Brain High Enough to Control HIVdone
CDC Issues H1N1 (Swine Flu) Guidance for People With HIVdone
GSK Studies Show No Increased Heart Attack Risk From Abacavirdone
March 2009 Success
Some HIV Drugs May Cause Pulmonary Hypertensiondone
Study: Reyataz Negatively Affects Blood Vessel Functiondone
Methadone and Protease Inhibitor Interaction Called Into Questiondone
HIV and Womendone
Drug Levels in Hair Predict Treatment Successdone
Call for a Coordinated Cure Effortdone
Africans and African Americans May Progress to AIDS More Slowlydone
Noninvasive Hep C Test Nearly as Good as a Biopsydone
Antiretrovirals Reduce AIDS Deaths, But Some Illnesses Remain Seriousdone
Low-Dose Efavirenz Safe for Somedone
Big Leap Forward in HIV Vaccine Sciencedone
Older Age Linked to Less Depressiondone
Lymphoma Drug Wakes Up Dormant HIVdone
HPV Infection Rates High in HIV-Positive MSMdone
Apricitabine Efficacy, Safety Hold Up Over 96 Weeksdone
Kidney Tube Dysfunction in Tenofovir Usersdone
More Help for Uninsured Patientsdone
Treatment Adherence: Still Importantdone
Neurocognitive Disorders, Poor Adherence in Older HIV-Positive Adultsdone
CD4 Cells Also Increase in HIV, Hep C Coinfectiondone
Innovative Video Captures Cell-to-Cell HIV Transferdone
One in Five HIV-Positive Women Drinks Heavilydone
Most South Carolina HIV Patients Not in Caredone
February 2009 Success
Tenofovir Kidney Toxicity in HIV-Positive Teensdone
New HIV Gene Therapy Starts Human Studiesdone
Therapeutic Drug Monitoring May Benefit People of Colordone
Shortage in HIV Providers Could Be Loomingdone
Isentress Gets Full FDA Approval for Experienced Patientsdone
Diabetes Drug Avandia Helps Reverse Lipoatrophydone
GS 9350 and SPI-452: Emerging Alternatives to Norvir Boostingdone
HIV Treatment Greatly Reduces, But Doesn’t Eliminate Transmissiondone
Kaletra-to-Isentress Switch Helps Lipids, but With Viral Rebound Riskdone
Start HIV Treatment Early—But When?done
IL-2 Fails in Two Large Studiesdone
Age, Diabetes & a Bigger Waist Line Tied to Cognitive Problems in HIVdone
PIs, Abacavir and Cardiovascular Disease: What’s the Risk?done
D:A:D Study: Reduce Modifiable Risk Factors to Improve Survivaldone
HIV Itself Is a Major Heart Disease Risk Factordone
Isentress Shows Long-Term Benefits in Treatment-Experienced Patientsdone
First Data From Injectable PRO 140 Studydone
Antidepressants Improve Viral Load Response to Treatment Due to Better Adherencedone
Microbicides Make a Comebackdone
Smoking Cessation: Hispanics, Nicotine Patch Users Do Bestdone
Nerve Damage Is a Common Problem in People With HIVdone
HDL and Small HDL Particles Predict Cardio Problems in HIVdone
Scientists Still Seeking Clues to Abacavir Heart Attack Mysterydone
Quarter of U.S. Positive Women Not Receiving Annual Pap Smearsdone
Aging and HIV a Destructive Combination on the Braindone
Psoriasis Drug Possibly Linked to Brain Infectiondone
Antiretroviral Highlights from CROIdone
Testosterone Therapy: Good for Women Toodone
Lymphoma: Death Rates Still High, but Cancer May Be Predicteddone
Sexually Transmitted Hepatitis C in MSM in the U.S. and Europedone
Peanut Recall, Salmonella Risk: Important HIV Informationdone
Half of Deaths in People With HIV No Longer From AIDSdone
Being Female Linked to Poorer Survivaldone
Two Rare Skin Cancers More Common in People With AIDSdone
HIV and Cancer: Prevalence and Preventiondone
HIV and the Brain: What to Watch Out Fordone
First HIV Gene Therapy Proves Safe With Hint of Effectivenessdone
Prevention Highlights, Part 1: PrEPdone
Treating HIV and Cancer With Radioimmunotherapydone
Prevention Highlights, Part 2: Treatment as Preventiondone
January 2009 Success
Up Kaletra Dose During Late Pregnancydone
Not Enough Antibodies to Protect Against Superinfectiondone
Starting HIV Treatment Early Restores Immune Cells to Normal Levelsdone
Missed Doctors Appointments Bad for Survivaldone
IL-2 Doesn’t Increase Lymphoma Riskdone
Premature Aging of CD4 Cells Linked to Faster Disease Progressiondone
Gilead Developing New Four-in-One HIV Drugdone
Blood Type Discovery May Lead to New Tools in HIV Fightdone
Poor Viral Control With Once-Daily Viramune, Viread and Epivirdone
Prezista’s Potency Enhanced by 2 HIV Mutationsdone
Project Inform Founder Martin Delaney Honored for AIDS Workdone
Kidney and Patient Survival Rates High in Positive Transplant Recipientsdone
Myriad Acquires Rights to Develop Bevirimatdone
No Evidence of Superinfection Between Long-Term Partnersdone
Marty Delaney, Founder of Project Inform, Diesdone
Earlier HIV Treatment Protects Against Hep C Liver Damagedone
HIV Treatment Boosts Lung Cancer Survival in People With HIVdone
New Heat-Stable Norvir Tablet Sent to FDA for Approvaldone
Non-AIDS Cancers on the Risedone
Once-Daily Better Than Twice-Daily HIV Treatmentdone
December 2008 Success
Latinos Most Likely, Blacks Least Likely to Have Lipodystrophydone
Proteins That Contain Selenium Reduce HIV Reproductiondone
Abacavir May Not Significantly Increase Inflammatory Proteinsdone
Prostate Cancer Treatment Works Well in HIV-Positive Mendone
Zoledronate Effectively Treats HIV-Related Bone Mineral Lossdone
HIV-Positive Women More Likely to Have Precancerous Anal Lesionsdone
Antibody Test Not the Best for Diagnosing Acute Hep Cdone
HPV Vaccine for Guys: Positive Early Datadone
Blocking CD8 Cell Receptor Prolongs Survival in Monkeysdone
Obesity Common in HIV-Positive Patientsdone
Treatment Adherence: Better Is Bestdone
Tesamorelin Diminished Gut Fat in Phase 3 Studydone
Thyroid Problems More Common in HIV Populationdone
High Rates of Metabolic Syndrome, Cardio Risk in Older People With HIVdone
Truvada, Viread and Emtriva Co-Pay Assistance Program Now Availabledone
Ziagen, Prezista Tablets Now Available for Childrendone
A Test to Predict Responses to Hep C Treatment?done
Does Smoking Reduce Kaposi’s Sarcoma Risk?done
Generic Zerit Approved in United Statesdone
Circumcision Prevents HIV Infection in U.S. Heterosexual Mendone
November 2008 Success
Major Updates to DHHS HIV Treatment Guidelinesdone
Truvada vs. Epzicom: The Debate Goes Ondone
Drug-Resistant Staph: Growing Concern Among People With HIVdone
High Number of Pulmonary Hypertension Cases in Naval HIV Cohort Studydone
Drug-Resistant Staph and HIV - Part 1done
Drug-Resistant Staph and HIV - Part 2done
HIV News at ICAAC/IDSA - Part 1done
HIV News at ICAAC/IDSA - Part 2done
Less Monitoring for Those Responding Well to Treatment?done
Stopping Treatment More Hazardous for People With Hep and HIVdone
Astragalus Extract May Strengthen Immune Response to HIVdone
HIV Can’t Hide From Specially Engineered CD8 Cellsdone
New GSK Program Reduces Out-of-Pocket Costs for HIV Medsdone
Lipoatrophy Associated With Weakening Hipsdone
Treatment Interruptions May Still Have a Futuredone
Small Study Fingers 'Silent' Heart Disease in HIV-Positive Mendone
Second-line Treatment Fails Twice as Often as First-linedone
Shutting Down an HIV Protein May Lead to Brain-Protecting Drugsdone
Cancer Risk Doubled in People With HIVdone
Once-Daily Intelence Could Work as First-line Treatmentdone
Risks Remain for Late Treatment Takersdone
Bavituximab: A New Strategy for Fighting Virusesdone
Rates of Drug-Resistant Staph Increasing in People With HIVdone
Selzentry Receives Full FDA Approvaldone
October 2008 Success
Delayed-Release Videx (EC) Now OK for Some Kidsdone
FDA Approves Boosted-Reyataz for Treatment First-Timersdone
Tenofovir Linked to Mild Decrease in Kidney Function, but Not Kidney Diseasedone
Pneumonia Hospitalizations Still High for Positive Patientsdone
Low CD4s in People With Hepatitis and HIV Associated with Liver Cancerdone
Merck Testing Once-Daily Isentressdone
Strength Training Burns More Fat Than Endurance Exercise in HIVdone
Single Dose of Diflucan Good for Thrushdone
New Anti-HIV Drug Target Discovereddone
Menopause, Tenofovir and Didanosine Increase Bone Lossdone
Third Dose of Hep A Vaccine May Increase Immunitydone
Treatment Interruption After an Early Start Produced Steep CD4 Declinesdone
50% of MRSA Skin Infections Return Within 1 Yeardone
Norvir and Viral Hepatitis Increase HIV Drug levels, Risk of Side Effectsdone
SMART Study: Viral Loads and Inflammation Explain Increased Cardio Riskdone
Prezista Approved for First-Time Treatment Takersdone
'Undetectable = Noninfectious' Debate Continues at U.K. Conferencedone
Blood Clots More Common in People With Advanced HIV Diseasedone
Isentress Comparable to Sustiva for First-Time Treatmentdone
Selzentry Reanalysis Shows Potential as First-Line Treatmentdone
Should ARV Treatment Be Started When CD4s Fall Below 500?done
PRO 140 Has Long-Lasting Activity Against HIVdone
Greater HIV Response to Prezista vs. Kaletra for First-Timers Over 96 Weeksdone
New NNRTI Called RDEA806 Shows Promisedone
Higher Response Rate with Norvir-Boosted Reyataz vs. Kaletra as First-Line Therapydone
OraSure Seeking FDA Approval for Rapid Hep C Testdone
EMD Serono Buys Rights to Sell Tesamorelin in U.S.done
Has HIV Evolved to Become More Dangerous?done
Long-Term Benefits and Risks of Kaletra Monotherapy Explored in Two Studiesdone
September 2008 Success
Norvir and Heart Conduction Disturbancesdone
Worsening Depression in Four Patients on Isentressdone
Vistide Not Effective in Treating PMLdone
Genes, Not Race, Should Guide Antiretroviral Treatmentdone
PAD Common in HIV-Positive Patients Over 50done
Researchers Link Gene to Key Antibody Responsesdone
High Rate of Circumcision Side Effects in Kenyan Surveydone
Further Possible Benefits of PrEPdone
HIV Status Unknown for Most “Negative” Men Onlinedone
People Now Able to Stay on First Antiretroviral Regimens Longerdone
HIV Stigma Hinders Access to Care and Preventiondone
Acyclovir Also Fights HIV in People With Herpesdone
Birth Defect Screening Just as Reliable in Positive Pregnant Womendone
Chamomile May Help Prevent Diabetes and Its Complicationsdone
New Maturation Inhibitor Enters Phase 2 Testingdone
Why Some Primates Aren’t Vulnerable to SIVdone
Relocation of Gut Bacteria Linked to Low CD4sdone
Twice-Daily Retrovir Now OK for Kidsdone
Nipple Shield Filters HIV From Breast Milkdone
HIV Treatment Diminishes Non-AIDS Illnessesdone
Tropism Testing May Help Predict Disease Progressiondone
Zetia Reduces LDL in People Living With HIVdone
Anti-Obesity Meds May Also Have Anti-HIV Benefitsdone
Once-Daily Prezista as Good as Twice-Daily Dose for Somedone
August 2008 Success
Discrimination Doesn’t Worsen Treatment Adherencedone
Annual HIV Infections in U.S. Substantially Higher Than Believeddone
Human Growth Hormone May Reduce Internal Fatty Depositsdone
Similar Survival Among IDUs on ARV Treatmentdone
Shortage of Health Care Workers Threatens African HIV Caredone
IAC Panelists: Scale Up, Leadership and Youth Crucial to HIV Responsedone
Report: Now Is Time to Prepare for PrEPdone
Some Gender and Racial Differences with Three Protease Inhibitorsdone
Isentress Continues to Show Well Versus Sustiva as First-Line Treatmentdone
Hep C: The Other Epidemicdone
Stigma, Fear of Side Effects, Keep Many off Treatmentdone
Sustiva Bests Kaletra for Treatment of Advanced HIV Diseasedone
NNRTI Rilpivirine (TMC-278) Comparable to Sustiva in 96-Week Studydone
Abacavir and Heart Attack Risk: Round 2done
Microbicides: Assessing Progressdone
Having Children a Priority for Many Positive Womendone
Achieving Universal Treatment Access: The Experience in Rural Malawidone
New NNRTI RDEA806 Shows Promise in Seven-Day Studydone
Abacavir and Cardiovascular Risk: Is There or Isn’t There?done
IDX899 Safe, Reduces Viral Load in Preliminary Studydone
Future Options for the Treatment Experienceddone
Isentress, Intelence and Prezista Combo Shines for Treatment Veteransdone
Studies Disagree on Abacavir for Patients With High Viral Loadsdone
New Options for Those New to Treatmentdone
Encouraging Data From Second Tesamorelin Study for Lipodone
Viread Receives Second Approval for Hep B Infectiondone
New HIV Numbers: New Prevention Strategy? Part 1done
New HIV Numbers: New Prevention Strategy? Part 2done
Defining the Risk Factors for Kidney Damage in Patients Using Tenofovirdone
Milk Thistle Shows Potential for Hep Cdone
Human Rights Struggles Define AIDS Fightdone
Norvir Tablets Similar to Capsules, Expected in 2009done
PrEP: Preparing For Success?done
Antiretrovirals Diminish Artery Hardeningdone
Vaccines: Lessons Learneddone
AIDS Activism For The Next Decadedone
Suicidal Thoughts Common in People With HIVdone
Rapid Hep C Disease Progression in HIV-Positive Mendone
Short-term Therapy May Help HIV-Related Depressiondone
New Drug Interaction Information With Reyatazdone
Non-Nukes and Triglyceride Levels Affect HDL Cholesteroldone
Cases of HIV Detectable in Semen, but Not Blooddone
Better HIV Treatment Response Seen in Older Patientsdone
PML Still a Risk and Often Progressivedone
Hormonal Contraceptives and HIV Disease Progressiondone
SMART Study Findings on Abacavir and Cardiovascular Riskdone
July 2008 Success
Montaner: Treat HIV to Help Curb Infection Spreaddone
CD4 Recovery Increases Asthma Risk in Childrendone
Bone Fractures More Common in HIVdone
Same Mortality Rates for Negative and Positive People 5 Years After Infectiondone
Guidelines Reiterate Resistance Testing for All New HIV Casesdone
Viramune Prescribing Information Updateddone
Fatty Liver Common in Patients With Metabolic Problemsdone
HIV Can Take Shortcuts to Reproducedone
Roche Abandoning In-House HIV Researchdone
Therapeutic Vaccine Tanks in Studydone
Blood Tests Could Replace Liver Biopsies for Hep Cdone
Progressive Resistance Exercise Good for People With HIVdone
Scientists Discover and Target HIV’s Weak Spotdone
Age Affects Response to Antiretroviral Therapydone
Genetics May Make Africans More Vulnerable to HIVdone
Blood Test Predicts Hep C Treatment Responsedone
Senate Reauthorizes PEPFARdone
Anal Cancer Rates Higher in HIV-Positive Mendone
Overactive Immune Systems May Cause the Bluesdone
Mediterranean and Low-Carb Better than Low-Fat Dietsdone
Gilead’s Elvitegravir Enters Phase III Studiesdone
Allergy Testing, Heart Risk Assessment Recommended Before Starting Abacavirdone
NRTIs Important as Component of Antiretroviral Therapydone
Kaletra and Efavirenz Affect Prednisolone Levelsdone
Life Expectancy With HIV Increases Dramaticallydone
Meditation May Benefit the Immune Systemdone
Deaths From Cancer, Liver and Cardiovascular Disease Growingdone
Efavirenz Doesn’t Worsen Hep C Treatment Side Effectsdone
June 2008 Success
Scientists Identify New HIV-Fighting Proteindone
Viracept Impurity Was Not at Cancer-Causing Levelsdone
Scientists Record HIV Particle Being Borndone
African HIV Breast Feeding Studies Show Benefitsdone
A New Improved HIV Tropism Testdone
Syphilis Treatment Response Improves With HIV Therapydone
Mediterranean Diet May Lower Diabetes Riskdone
Combining Invirase and Garlic Capsules Not Recommendeddone
Neuropathy Skin Patch Reduces Paindone
Coinfection With HIV and HCV in Pregnancydone
Scoring Tool Helps Predict KS Worseningdone
Experimental HIV Drug Hits Snagdone
Epilepsy Drug Doesn’t Reduce HIV Reservoirdone
Tibotec Launches Medication Reminder Servicedone
Confirmation of Tesamorelin’s Lipo-Fighting Potentialdone
Crack Is Wack in Women’s HIV Studydone
HIV Hospitalizations Halved Since 1994done
Experts Recommend Heart Disease Screening in HIVdone
Cheaper Test for Atherosclerosis Works in HIVdone
Reyataz Approved for First-Line Use in Europedone
Deep Vein Clotting Risk Higher in HIVdone
Zinc Fingers to the Foredone
May 2008 Success
Rate of Heart Attacks Stable Despite Increased Riskdone
“Video Doctor” Reduces Unsafe Sex and Drug Usedone
Stimulated Cells Control SIV, and Hopefully HIVdone
Experimental HCV Treatment Shows Real Promisedone
New Report: Some ADAPs Cover HCV Treatmentdone
Majority of Patients Will Be Able to Use Intelencedone
Antiretrovirals Vital in Treating Cancerdone
Higher-Dose Kaletra Plus Rifampicin Creates Liver Toxicitydone
Bone Marrow Deficits May Explain Blunted CD4 Responsedone
Spying on an HIV Enzymedone
Can Antidepressants Also Boost the Immune System?done
GSK Hasn’t Mentioned Heart Attacks Reported in 2005 Letterdone
High Cholesterol Good for Hepatitis C Treatment?done
Immune Cells Harbor Infectious Virusdone
New Developments in Abbott’s Norvir Court Casedone
GSK Responds to Accusations About Abacavirdone
Viracept OK Again for Children, Pregnant Womendone
New HIV Drug Discoverydone
Lingering Side Effects Reported With Facial Fillerdone
Anal and Other Cancer Rates Higher in HIVdone
Thalidomide Helps HIV-Related Colitisdone
Good Results in Long-Term HCV Treatment Follow-Updone
Latinos Respond Less Well to HCV Treatmentdone
Gold Nanoparticles Revive HIV Drug’s Prospectsdone
Monitoring Board Finds HIV Combo Inferiordone
Norvir-Boosted Protease Regimen Bests Other Regimensdone
Calming the Immune System to Treat HIVdone
April 2008 Success
Evolutionary Accident Makes HIV Deadlydone
Even Failing Treatment Reduces HIV in the Braindone
Bad Teeth Also Bad for Young Men’s Heartsdone
High Triglycerides Linked to Fat Abnormalitiesdone
Combined Resistance Analysis Better Predicts Treatment Failuresdone
Guidelines Panel Leaves Abacavir Recommendations Unchangeddone
Hepatitis B Coinfection Doesn’t Affect HIV Treatmentdone
Hetero Men Also at Risk for Anal HPVdone
ADAP Recipients Hit All-Time High in 2007done
Most U.K. Patients Start Treatment Without HIV Resistance Infodone
Managing Prostate Cancer No Different in HIVdone
Tesamorelin for Lipo: More Data Expecteddone
Vicriviroc Trial Enrolling Treatment First-Timersdone
HIV Immunotherapy Shows Promisedone
Tropism Predicts CD4 Loss, Not Treatment Responsedone
Sexual Dysfunction Linked to Poor Treatment Adherencedone
African Americans Have Rapid Kidney Disease Progressiondone
Insulin Resistance Predicts Heart Disease and Stroke Riskdone
CD4s Predictive of Non-AIDS-Related Health Problemsdone
Treatment Failure: Symptoms Matter Toodone
Better Antibiotics for Second-Line PCP Treatmentdone
HIV Affects Body Shape and Lipids in Womendone
Interfering with Immune Protein Slows HIV Reproductiondone
Improving the Predictive Ability of a Resistance Testdone
March 2008 Success
Disalcid Improves Inflammation, But Has Liver Toxicitydone
Pneumonia Vaccine Effective in HIVdone
HIV-Positive Women Remain Slimmer but Have Higher Waist-to-Hip Ratiosdone
Neuropathy Pain Patch Fails Testdone
Bevirimat Success Hinges on HIV Mutationsdone
Genetically Reprogrammed Cells Could Battle HIVdone
Test for Abacavir Hypersensitivity Works in Black and White Patientsdone
Fish Oil and Fenofibrate an Effective Combo for High Triglyceridesdone
Mentally Ill and Substance Users Not Getting Caredone
Prezista Warning: Liver Problems Possibledone
Race and Gender Impact HIV Treatment Side Effectsdone
Trust for Doctors High in French Studydone
Universal Health Care Doesn’t Ensure Universal HIV Treatmentdone
Mental Illness and Substance Use Delay HIV Treatmentdone
Some Genetically Protected Against Lipoatrophydone
Tenofovir Better Tolerated Than Zidovudine for PEPdone
PIs Increase Heart Disease Risk, and NNRTIs Decrease Itdone
Group Psychotherapy Improves Mood, but Not Adherencedone
Food Poisoning May Be Fatal for People With HIVdone
Charting the Future of Protease Monotherapydone
Lower-Dose Zerit May Improve Some Side Effectsdone
Some People Not Appropriately Treated for High Cholesteroldone
More HIV Cases Reported in 2006done
Genes Predict Immune Response to Antiretroviral Treatmentdone
February 2008 Success
Parasitic Drug Shows HIV-Fighting Promisedone
Gilead Loses Key Patents on Tenofovirdone
Vicriviroc Shows Well in Treatment-Experienced Patientsdone
Abacavir, Didanosine Linked to Increased Heart Attack Riskdone
Norvir/Reyataz Comparable to Kaletra for First-Line Therapydone
Sexual Reinfection With HCV Following Treatmentdone
AIDS Survival: Progress Not Perfectiondone
Once- vs. Twice-Daily Kaletra Tablets: Similar Safety and Potencydone
Epzicom Comparable to Truvada as First-Line NRTI Choicedone
Male Circumcision Doesn't Reduce Women's HIV Riskdone
TDM-Guided PI Dose Increases of Limited Benefitdone
Refining HIV Treatment for New Med Takersdone
Prevention and Women: HIV-positive and HIV-negativedone
Once-Daily Viramune Is at Least as Efficient as Twice-Daily Dosingdone
Durable Efficacy Seen in Studies of New NNRTI Intelencedone
Nanotechnology May Yield Long-Lasting Medsdone
HIV & Your Heart: Part Idone
HIV & Your Heart: Part IIdone
Morris Jackson: Survivor and Treatment Activistdone
Prezista Effective and Safe in Positive Kidsdone
Durable Efficacy and Safety With Isentress Treatmentdone
Good Bacteria Reduces Vaginal HIV Levelsdone
New Hope for Treatment Experienceddone
Extended-Release Viramune Begins Studydone
VIRxSYS Gene Therapy Makes Progressdone
Women & HIV Treatmentdone
World of Prevention: Vaccines and Moredone
Condom-Free Sex? Controversial Swiss Declarationdone
Acyclovir Doesn’t Reduce HIV Infection Risk in HSV-2-Positive Peopledone
Suppressing HIV Improves Kidney Functiondone
HIV Treatment Improves, but Doesn’t Restore, B Cellsdone
Starting Treatment With Higher CD4s Cuts Death Ratedone
Dipstick Kidney Test Less Accurate in HIVdone
Study Links Zerit and Retrovir With Diabetes Riskdone
Drug Use Linked to Infection With Resistant Virusdone
Discordant Responders Have Faster Disease Progressiondone
Growth Hormone Boosts Thymus T-Cell Productiondone
New Prezista 600 mg Tablet Approveddone
GeoVax Vaccine to Move Forwarddone
Safe for Some to Switch to Viramune With Higher CD4 Countsdone
Epzicom Efficacy Concerns Lead to ACTG Study Changesdone
GSK Comments on ACTG 5202 Study Changesdone
HIV Treatment Increases Survival, Not Heart Attack Riskdone
January 2008 Success
Antiretroviral Therapy Reduces HIV in Lungsdone
Peripheral Arterial Disease Risk Found in People With HIVdone
FDA Clears Quick Test for Drug-Resistant Staphdone
Potential Drug Interaction Between Sustiva and Dilantindone
Antiretrovirals Don’t Increase Heart Disease Riskdone
Drug Interaction Caution With Crestor and Kaletradone
Following Treatment Guidelines Generates Best Resultsdone
Hepatitis B Revaccination Effective in People With HIVdone
More Heart and Kidney Problems in Treated African Americansdone
Recreational Drug Use Had Little Effect on Immune Cellsdone
Zetia Doesn’t Reduce Artery-Clogging Plaquesdone
HIV Blocking Proteins Found in Dendritic Cellsdone
New Multi-Drug-Resistant Staph Infections Plaguing Gay Mendone
Low Testosterone Increases Bone-Fracture Riskdone
Acid Reflux Meds Allowed With Reyatazdone
Low-Dose Interferon Shows Potential for Hep Cdone
Kaletra Monotherapy Disappointsdone
Tibotec’s Intelence (Etravirine, TMC125) is Approved by FDAdone
Stigma From Health Care Providers Toward People With HIVdone
Antiretrovirals Significantly Increase Survival in HIV-Positive Childrendone
Antiretrovirals, Cocaine Use Associated With “Silent” Heart Diseasedone
Swiss Study Finds Less Lipodystrophy in Recent Yearsdone
DHHS Issues Changes to U.S. Treatment Guidelinesdone
Treatment Interruptions Lower Quality of Life in SMART Trialdone
High Rate of Bone Problems in French HIV Patientsdone
Selzentry May Hold Promise for HIV Preventiondone
December 2007 Success
Plan to Reduce Late HIV Diagnoses in Europedone
Black MSM Have Higher HIV Rates Despite Similar Risksdone
HIV Testing? Not in My ERdone
Non-Injection Drug Use Linked to Greater HIV Infection Riskdone
Circumcision Not Protective in U.S. Gay/Bisexual Mendone
HIV Rates Declining in Some Older Americansdone
HIV Rates Increasing Most in Young Black Gay/Bisexual Mendone
Sodomy Laws Bad for HIVdone
Serious Mental Illness and Addiction in Newly Diagnoseddone
Party Drug Use Waning in NYC Gay and Bisexual Mendone
Newly Infected People Change Risky Behaviors After Diagnosisdone
High Rate of False Positives at DC Clinicsdone
Are We Ready for PrEP?done
Tesamorelin KO’s Belly Fatdone
DHHS Unveils Revised U.S. Treatment Guidelinesdone
Hep C Treatment Response at Week 4 Predicts Successdone
Viread With Boosted PIs Worse for Kidneysdone
Viramune Protective Against Hep C Liver Damagedone
Triple-Class Drug Failure Uncommon After 10 Years of HAART Usedone
Gilead & BMS to Market Atripla in Europedone
HAART Improves Survival With Hodgkin’s Lymphomadone
IVIG Reduces Immune Activation, Boosts CD4 Cellsdone
Fish Oil Plus Fenofibrate Good for High Triglyceridesdone
Atripla Approved in Europedone
Drug Holidays Dangerous for Treatment-Experienceddone
Trofile Bests SensiTrop as Most Reliable Tropism Testdone
Isentress Wins Approval in European Uniondone
First-Line Therapy Approval Requested for Prezistadone
Asymptomatic Ischemia Common in HIVdone
Viral Load During Pregnancy: Lower the Betterdone
HIV-Positive Women Have Higher Risk of Bone Fracturesdone
Impact of CD4s on HCV Treatment Uncertaindone
November 2007 Success
Early Treatment Reduces Risk of Three Common Complicationsdone
GSK Discontinues Agenerase Liquid and 50mg Capsulesdone
Major Lab Company Licenses Tropism Testdone
Half of Patients Had AIDS at Time of HIV Diagnosisdone
New Guidelines on Treatment of Pregnant Women Releaseddone
New Worries With AIDS Vaccinedone
Single-Dose Drug Combination Reduces Non-Nuke Resistance Risk for Moms and Kidsdone
Immune Reconstitution Inflammatory Syndrome (IRIS) Risk Factors Identifieddone
People With Kidney Disease Undertreated for HIVdone
GSK Sues Abbott Over Norvir Price Hikedone
FDA Approves Low-Dose Kaletra for Kidsdone
Herpes Drug Fights HIV Toodone
Suppressing HIV Doesn’t Stop Immune Activationdone
High Rate of HIV Superinfection Found in Kenyan Sex Workersdone
Metabolic Syndrome Increases Risk for Diabetes and Heart Disease After Starting Treatmentdone
AIDS Activism Training in Atlanta, December 7 & 8done
Avandia Negatively Affects Cholesterol in HIV-Positive Patientsdone
Fosamax Safe and Effective for Bone Mineral Lossdone
HIV, ARVs Don’t Increase Blood Pressure Riskdone
Sculptra Modestly Improves Facial Wastingdone
Treating Anal Lesions Nonsurgicallydone
October 2007 Success
Acetyl-L-Carnitine Promising for Neuropathydone
Tesamorelin Promising for Lipodystrophy Over 52 Weeksdone
Scientists Discover a Way to Reach Hidden HIVdone
Key Protein Blunts Immune System’s Power to Fight HIVdone
Needle-Free Fuzeon Abandoned for Nowdone
Better Quality of Life for People With HIV Who Quit Smokingdone
HIV Treatments Protective Against Brain Damagedone
Stress May Contribute to HIV Disease Progressiondone
People on a Failing HIV Regimen May Still See Benefitdone
Women Aren’t Talking Treatment With Their Docsdone
New Study Finds Alcohol Use and Depression Influence Adherencedone
Isentress Gets FDA Approvaldone
Norvir Dose Lowered for Use With Lexivadone
Rapid Liver Damage Possible in HIV/HCV Patientsdone
Researchers Recommend Screening for Pulmonary Arterial Hypertensiondone
Today's Patients Seek HIV Care Later Than Those in 1990done
HIV Increases Risk of Heparin-Induced Thrombocytopeniadone
Committee Recommends Approval of Atripla in Europedone
ESRD Nearly Six Times Higher in African Americans With HIVdone
Low Body Weight, Not HIV, Linked to Frail Bonesdone
Kaletra Reduces HIV in the Braindone
Poor Adherence May Explain Worse Sustiva Responses Among Blacksdone
Strategies for Success With Kaletra Monotherapydone
More Promising Data on Selzentry for Drug-Resistant HIVdone
Aiming Low: 'Undetectable' Not Just for Treatment Newbiesdone
Safer Family Planning for Positive Couplesdone
Why Do Those With HIV Have More Heart Attacks?done
Rilpivirine Comparable to Sustiva in Treatment First-Timersdone
More Rash With Once-Daily Viramunedone
Similar Efficacy, Better Triglycerides with Invirase vs. Kaletradone
Tesamorelin (TH9507) Safe and Effective for 52 Weeksdone
Alive and Well: Ten Years of HAART in Advanced HIV Cohortdone
Crestor Bests Pravachol for Elevated Lipidsdone
New Menu of Antiviral Optionsdone
Children and Challenges: Treating Pediatric HIVdone
Kaletra Tablets for Children Show Equivalencydone
Small Steps Forward in HIV Preventiondone
Is Once-Daily Kaletra an Effective Dosing Option?done
Pre-treatment CD4 Count Predicts CD4 Gains on Treatmentdone
HIV Treatment Greatly Improves Brain Illness Survivaldone
September 2007 Success
Needle-Free Device Improves Life for Fuzeon Usersdone
Metformin Shows Little Lipodystrophy Benefit in Small Studydone
Promising New Nuke, Apricitabinedone
Isentress Recommended for FDA Approvaldone
Study Suggests Treating Hep C Before HIVdone
High-Fat Diets Affect Disease Progressiondone
Pfizer Warns of Cancerous Impurity in Viraceptdone
HIV Damages Brain Despite Treatmentdone
Lasting CD4 Increases With IL-2done
More Reports on Kidney Stones With Reyatazdone
Pregnancy Protective Against HIV Disease Progressiondone
Skin Test Predicts Control of HPVdone
High Risk of Peripheral Artery Disease in HIVdone
Lexiva and Kaletra Comparable in Long-Term Studydone
Interview with a Hep C Activist & Survivordone
Heart Disease Risk Remains in Absence of HIV Treatmentdone
Prezista Shows Well in Patients New to Treatmentdone
Isentress Offers Long-Term Benefits for Drug-Resistant Patientsdone
Secrets of a Long-Term Survivordone
Coming Down the Pike: Expanding HIV Treatment Optionsdone
IL-2 May Delay Need for Antiretroviral Treatmentdone
Elvitegravir Study Highlights Value of Strong Background Regimendone
New Data Explores Current Treatment Optionsdone
Wisdom for Women: An Expert's Take on HIV and Gender Differencesdone
Selzentry Treatment Failure: The Impact of Tropism Changesdone
Two-Year Vicriviroc Benefit in Treatment-Experienced Patientsdone
FDA Grants Priority Review for New NNRTI, Etravirinedone
HIV Prevalence Declines in Pregnant Women in Zimbabwedone
Single-Dose PRO 140 Has Lasting Effectsdone
48-Week Selzentry Data Show Promise for Drug-Resistant HIVdone
Etravirine for NNRTI-Resistant HIV: Pooled DUET Study Resultsdone
Activist Seek Fair Price for Isentressdone
Maraviroc Gets EU Approvaldone
High Rate of Kidney Problems in HIVdone
Dry Skin More Common in Positive Peopledone
Genetic Tests Could Help Reduce Sustiva Side Effectsdone
Ban on European Viracept Sales Lifteddone
KP-1461: A New Approach to HIV Treatment Now in Studiesdone
Past Lexiva Treatment May Reduce Benefit From Prezistadone
August 2007 Success
Lexiva vs. Reyataz: Comparable Efficacydone
PRO 140 Shows Promise in Single-Dose Studydone
Prezista Superior to Kaletra for Treatment-Experienced Patientsdone
NNRTI Etravirine Effective for Treatment-Experienced Patientsdone
Pfizer's Selzentry Gets FDA Approvaldone
Women Do Better on Tipranavir/Ritonavirdone
Europe Suspends Viracept Salesdone
Non-AIDS Cancer Risk Higher for People with HIVdone
HPV Vaccination For All Positive Gay Men?done
Nukes, not PIs, Tied to Diabetes in Positive Womendone
High CD4s No Guarantee against AIDS and Deathdone
Infant Dies of Kaletra Overdose, Prompts Warningdone
New Infection Symptoms Affect Viral Load, Speed to AIDSdone
Good Treatment Results for Over 50sdone
Higher Risk of C-Section Complications in Positive Womendone
Cost Shouldn’t Be Obstacle to Lipo Treatmentdone
HIV’s Two-Pronged Attack on the Braindone
Kidney Problems Require Careful NRTI Dosingdone
Scientists Say Internet Gives AIDS Denialists New Lifedone
New Blood Test for PCP Holds Promisedone
Put All Your Pills in One Basketdone
Fat Buildup Increases Insulin Resistance Riskdone
Are Viral Load 'Blips' Really Harmless?done
Marijuana or Marinol? Both Show Benefitsdone
Nukes, Not PIs, Linked to Diabetes Riskdone
Memantine May Help Prevent, Not Treat, Dementiadone
Zero Infections in Large Sperm Washing Studydone
Pneumococcal Vaccine Effective in Positive Peopledone
July 2007 Success
HIV Treatment Increases Risk of Diabetesdone
Children's Sustiva Dose May Need to be Uppeddone
Prezista/Norvir Bests Kaletra in Treatment-Experienced Patientsdone
Dynamic Duo Etravirine and Prezista Shine in Studiesdone
HIV Increases Lung Cancer Riskdone
Zetia Helps Lower Lipid Lipids in HIVdone
New Method Identifies Rare Resistance Mutationsdone
HIV Treatment Boosts Birth Ratedone
Despite Flu Shot, Flu Often Occurs in HIVdone
Treatment Access Isn't Just a Global Issuedone
No Lipodystrophy Approval for Serostimdone
Tenofovir's Long-Term Safety Profiledone
Celsentri (Maraviroc) Interaction Warningdone
AIDS Down Under: IAS Conference Begins in Sydneydone
Fauci Defends Bush's AIDS Legacydone
Crystal Meth Linked to Lower CD4s in Positive Peopledone
Timed Intercourse Plus PrEP for Low-Risk Natural Conceptiondone
An Eccentric Professor Expounds on Growing Old With HIVdone
Are We Starting Treatment Early Enough?done
Merck’s Isentress Comparable to Sustiva as a First-Time Treatmentdone
HIV Infection Linked to Higher Skin Cancer Riskdone
Rilpivirine (TMC-278) Has Metabolic Edge Over Sustivadone
Vicriviroc Shows Benefits, Continues Developmentdone
A Positive Papua New Guinean Speaks Out Against Stigmadone
The Latest on Lipo: Advances & Setbacksdone
Which HIV Meds Cause Lipoatrophy?done
Sustiva Edges Out Celsentri in Treatment Newbiesdone
Simple Test Can Help Prevent Abacavir Allergydone
High Risk of Kidney Problems in HIVdone
Pipeline Preview: All The New AIDS Drugs Coming Soondone
Simple Test Eliminates Abacavir Riskdone
Norvir/Invirase Go Head-to-Head with Kaletradone
Starting or Switching: Truvada Outpaces Combivir in Studiesdone
Is HIV Treatment Actually Reducing Heart Attack Risk?done
Beyond Condoms: Medical Approaches For Preventiondone
June 2007 Success
Early Treatment may have CD4 Advantagedone
New Drugs Possible from Discovered HIV Transport Systemdone
Roche's Viracept Recalled; Pfizer's U.S. Version Okaydone
People with HIV May Need Longer TB Treatmentdone
LDL Drops with Sustiva to Viramune Switchdone
Twins Pregnancy Carries Greater HIV Riskdone
Non-Nuke Shows Early Promise as Microbicidedone
Racially and Gender Diverse Aptivus Study Underwaydone
Several Factors Raise Women's Bone Loss Riskdone
Reyataz May Cause Kidney Stonesdone
Death Rates Higher Among Rural Positive Patients - But Why?done
Maraviroc: Approvable, but not yet Approveddone
Hep B and HIV Baraclude Users Bewaredone
Panacos' Bevirimat Back on Trackdone
Drug-Resistant HIV in Semen Stirs Concernsdone
Dietary Supplement Rule Announced, Questioneddone
Treatment Improves Survival Among IDUsdone
Neuro Problems may Persist with Treatmentdone
HIV, PIs Don't Lead to Artery Thickeningdone
Designer Enzyme to Fight HIV Shows Promisedone
Polyalkylimide Injections Improve HIV Lipoatrophydone
Children with HIV Face Increased Heart Disease Riskdone
May 2007 Success
PRO 140 Has Potent and Lasting HIV Effectdone
Race, Mental Health Affect HIV Treatmentdone
HAART to Heart: It’s Not Just the Medsdone
Possible Lipo Drug Dropkicks Glucosedone
HIV Treatment Good for Growth in Kidsdone
Uncommon Causes of Stroke More Frequent in HIVdone
Green Tea for HIV Dementiadone
Glitazones Not Likely Useful for Lipoatrophydone
Study Explores Lipid Problems in Womendone
Hysterectomy Rates Higher in Women with HIVdone
PIs and Non-Nukes Cause Similar Metabolic Problemsdone
No Drop in Non-AIDS Cancer Ratesdone
Kaletra Regimens 'Forgiving' of Missed Dosesdone
Study Finds Abacavir Allergy Screening Usefuldone
Pubic Lipomas a Lipo Symptom?done
Regular Healthcare Visits a Key to Survivaldone
HIV Vaccines May Work in Unexpected Waysdone
Accurate Immune System Marker in Poor Countriesdone
Spinal Chemicals May Predict HIV Dementia Riskdone
'Runaway' Theory Doesn't Explain Slow CD4 Lossdone
Some Do Well After Treatment Interruptiondone
'Serosorting' Risk can be Highdone
Lipid Problems Explored in Womendone
April 2007 Success
GSK Reports Combivir and Ziagen Tamperingdone
Large Study Links Meth Use and HIV Riskdone
48-Week Prezista Data Publisheddone
Home HIV Test in the Worksdone
Rabies: An HIV Therapy?done
571 on ADAP Waiting Listsdone
Natural Molecule in Blood Blocks HIVdone
First CCR5 Blocker Gets Vote of Approvaldone
March 2007 Success
Once-Daily Viramune Strikes Outdone
Fewer Side Effects with Videx/Epivir vs. Combivirdone
Integrase Inhibitor Elvitegravir (GS-9137) Shows Welldone
Non-Nuke TMC-278 Comparable to Sustivadone
HIV+ Less Responsive to Lipid-Lowering Medsdone
Study Says Less Fat for Lower Lipidsdone
Baraclude Induces HIV Drug Resistancedone
Still No Clear Benefit of Treating Early HIVdone
Twice-Daily Kaletra Possibly Better for Some Patientsdone
Study Finds Viread Advantages in Black Patientsdone
Mental Illness Affects HIV Treatment Responsesdone
Black HIV/AIDS Rates Disproportionately Highdone
Testosterone Doesn't Build Muscle in Wastingdone
Early HCV Response Predicts Outcomedone
Sharp Drop in Hepatitis Casesdone
Apricitabine Useful for Drug-Resistant HIVdone
Less Lipo and Better Lipids with Ziagen vs. Zeritdone
Poz Kids Can Maintain Stable CD4sdone
HPV Vaccine May Slow HIVdone
Counseling Can Reduce HIV Spreaddone
Fish Oil Lowers Lipids in HIVdone
WHO & UNAIDS: Male Circumcision Recommended to Slow HIV Spreaddone
Green Tea for HIV?done
February 2007 Success
Asthma Med for IRIS?done
Despite Setback, Advocates Push for Continued Microbicide Researchfailed
Hep C: Heavy Drinking Riskier for Women than Mendone
HIV Rates Drop Among Florida Blacksdone
GSK Offers $50 Savings Card to Lexiva Usersdone
IL-7 May Protect CD4 Cells in HIVdone
PN Study Supports Medical Marijuanadone
Metabolic Syndrome No More Common in HIVdone
Herpes Raises Pregnancy Transmission Riskdone
Protein Discovery May Aid Vaccine Developmentdone
Prezista Receives European Approvaldone
Disclosure May Boost CD4 Countsdone
Are We Spending Too Much on HIV?done
HIV Protein to Fight Cancerdone
Low Risk of Premature Births with HIV Treatmentdone
Fosamax, Calcium, and Vitamin D for Bone Weaknessdone
Zetia Lowers 'Bad' LDL Cholesteroldone
More Lipoatrophy with Sustiva vs. Kaletradone
Double-dose Viread effective against NRTI-resistant HIVdone
One in 10 Infected with Drug-Resistant HIVdone
TH9507 Shows Promise for Lipodystrophydone
Breastfeeding Safer for Some HIV+ Mothersdone
Isentress (MK-0518) Results Prove Promisingdone
Encouraging Data from Two Maraviroc Studiesdone
Shift in Cancer-Related Deaths in HIVdone
January 2007 Success
Risk of HIV Shedding Greater With NNRTIs Than PIsdone
Abacavir in Kids with HIV-Associated Encephalopathydone
WSJ Uncovers Abbott's Norvir-Busting Marketing Strategiesdone
A More Sensitive Drug Resistance Testdone
High HIV Lung Cancer Risk (Not Just From Smoking)done
Early Treatment Linked to CD4 Gainsdone
Nevirapine Works After Use in Pregnancydone
'Serosorting' Appears To Be Limiting Spread of HIVdone
AIDS Dementia Predicts Time to Deathdone
Lifespan Expanding for Patients with HIVdone
Risk of BCG Infection in Positive Infantsdone
Selenium Treatment Beneficial in HIVdone
PIs Increase Carotid Thickness in Womendone
Hundred-Fold Greater Risk of Osteonecrosis in HIVdone
Leishmaniasis Drug Stimulates HIV Replicationdone
After the Hype, Depakote no Cure for HIVdone
December 2006 Success
Routine Testing Is Cost Effectivedone
Lipolytic-Blocker Improves Metabolic Profiledone
CD4s in Gut Respond Poorly to Treatmentdone
Gel Condom to Prevent HIVdone
Drug Combo for High Cholesteroldone
HIV and Treatment Raise Risk of Bone Weaknessdone
Many Factors in Treatment Hepatotoxicitydone
Long-Term Data on Combivir vs. Viread/Emtrivadone
Early Therapy for HIV/HCV Coinfecteddone
GSK Halts PI Brecanavirdone
Cotrimoxazole Improves Pregnancy Outcomesdone
High Rates of Drug Resistance Among Teensdone
Good News for HIV Positive Surgical Patientsdone
TH9507 Causes Modest Fat Drop in Lipo Studydone
Maturation Inhibitor Bevirimat Hits Dosing Snagdone
HAART Tied to Hodgkin's Lymphomadone
NNRTIs May Have Edge in HIV Therapydone
Gag Reflex: HIV Protein Should Be Vaccine Targetdone
Radiesse Approved for HIV Lipoatrophydone
Immunotherapy May Enhance HIV Therapydone
HIV Suppressed More in CSF Than Plasmadone
November 2006 Success
HIV Infects Epithelial And Brain Cells Lacking CD4done
HIV Treatment: That'll be $618,900, Pleasedone
Making (Anti)sense of Gene Therapydone
Indian Alert on Faulty HIV Testsdone
New U.S. HIV Cases Cost $12 Billion a Yeardone
Once-daily lopinavir/ritonavir effective in HIVdone
Monoclonal Gammopathy in People With HIVdone
Making Babies the Old-Fashioned Waydone
Gene Therapy for HIV Infection Shows Promisedone
Success With Radioactive Antibody Therapydone
Zinc Supplements Don't Improve Diarrheadone
Boosted Invirase vs. Kaletradone
Vaginal Infections Declinedone
Innate Factors May Block HIV in Womendone
Radiolabeled Antibodies Kill HIV-1-Infected Cellsdone
Treatment Interruption No Benefit to Multidrug Resistantdone
Belly Fat Gains no More Common in HIVdone
Imiquimod for Anal Intraepithelial Neoplasia?done
HIV Infection On The Rise Worldwidedone
Adding Enfuvirtide Doesn't Helpdone
Treatment Adherence Depends on Many Factorsdone
Gorilla Virus Source of Some HIV Infectionsdone
Psychiatric Disorders Make HIV Treatment Costlydone
Micronutrient Deficiency Rare in Treated Patientsdone
World AIDS Day Report: "Millions of Lives at Risk"done
Not So SMART: Interruption Strategy Questioneddone
COPD More Likely in Patients With HIVdone
Thymidine-Sparing Regimen Improves Lipoatrophydone
October 2006 Success
ICAAC: Norvir-Boosted Lexiva vs. Reyatazdone
ICAAC: Trizivir vs. Reyataz/Combivirdone
Diet and Exercise Fight Metabolic Syndromedone
Tenofovir Prodrug Delays SHIV Infectiondone
AIDS Activist With Baboon Marrow Transplant Diesdone
Bacteria Protein Prevents HIV Entrydone
Course Of HIV Neurologic Disease Variable, Related To Platelet Countdone
Animal Study Indicates Alcohol May Accelerate HIV Progressiondone
AIDS activist with baboon marrow transplant diesdone
Enfuvirtide As Rescue Therapy in Med-Experienceddone
Enfuvirtide As Rescue Therapydone
Tyzeka Approved for Hepatitis Bdone
Vulnerable HIV Patients Less Likely To Have Caredone
Vaccine Series Safe In Childrendone
Medecins Sans Frontieres Founder Wants Stronger WHOdone
Boosted Atazanavir Of Mixed Benefit In Pediatric HIVdone
Progression-Free Survival Common For Pregnant Womendone
New Treatment Guidelines for HIV-Positive Childrendone
September 2006 Success
Greater Risk of Bone Loss in HIV-Positive Womendone
Standard Dosage Works for Overweightdone
EAP Launched for First Integrase Inhibitordone
Treating Primary HIV Infection: Is There a Benefit?done
CDC Recommends Routine HIV Testingdone
Smokers May Be at Greater Risk of HIV Infectiondone
ICAAC: MK-0518 Appears Lipid Friendlydone
ICAAC: Abortion Pill for HIV? Questions Still Remaindone
Prezista Women's Study Opens for Enrollmentdone
ICAAC: Predicting Responses to Aptivus or Prezistadone
ICAAC: MK-0518 Potent for Treatment Experienceddone
ICAAC: More Drug-Resistant HIV?done
ICAAC: Prezista and Aptivus on Drug-Resistant HIVdone
Predictive Value of Viral Load Testing Questioneddone
August 2006 Success
New Genetic Test Ready for Prime Time?done
HIV Hides from Treatment in the Gutdone
Dosing Questions May Slow TNX-355 Developmentdone
Lipodystrophy in Women: More Data from FRAMdone
IAC: Serostim As Immune-Based Therapy?done
IAC: Four Drugs Vs. Threedone
IAC: Encouraging Data on Etravirine (TMC-125)done
IAC: 48-Week Prezista POWER Results Presenteddone
IAC: Tibotec VP Discusses Latest On Prezistadone
IAC: Markowitz on the Supervirus Casedone
IAC: Nutritional Boost CD4 Countsdone
IAC: Meds Improve Growth and Body Compositiondone
IAC: Fauci Gets Grilleddone
IAC: Activist Gonsalves Slams Gates & Clintondone
IAC: Challenges of Reaching Countries in Needdone
IAC: Lexiva Measures Up to Kaletradone
IAC: Maraviroc Less Effective but Safe for Somedone
IAC: Vicriviroc Shows Promisedone
IAC: Data, Access for Integrase Inhibitordone
IAC: Encouraging TNX-355 Datadone
IAC: Growth Hormone for Lipodone
IAC: Lead Researcher Discusses KLEANdone
IAC: Markowitz on MK-0518done
IAC: Kotler Responds to Critics of FRAMdone
IAC: Sustiva vs. Kaletra? We Have a Likely Winnerdone
IAC: Is Kaletra Monotherapy Possible?done
T-Cell Protein May Be HIV Treatment Opportunitydone
Topical Version of Protease Inhibitor May Treat HPVdone
Second Facial Filler for HIV Lipoatrophy Receives Approval Recommendationdone
July 2006 Success
New Aptivus Warning: Bleeding in the Braindone
One-Pill, Once-Daily Combo Approveddone
Doctors, Patients Disagree on Resistance Concernsdone
Study Confirms Treatment Benefit for Childrendone
I Forgotdone
An HIV Drug Says Goodbyedone
Pregnancy Treatment Guidelines Reviseddone
June 2006 Success
Making the Link: Chimps Believed Source of HIVdone
Got Milk? Don't Let Dairy Get You Downdone
Aptivus Study Halteddone
HIV Vaccines: They're Not Perfect But...done
HIV's Wicked Ways: An Accident of Evolution?done
Protease Inhibitor Prezista Approveddone
Activists Say New HIV Drug Price Encouragingdone
HIV/AIDS Treatment: Three Million Years of Life Saved in U.S.done
May 2006 Success
Updated Treatment Guidelines Publisheddone
Survey: HIV Docs and Patients Don't Always See Eye-to-Eyedone
Lexiva vs. Kaletradone
Entry Inhibitor TNX-355: New Phase 2 Study Datadone
Covering Our Asses: A Healthcare Provider Questions CDC HPV Informationdone
HPV Vaccine Receives Approval Recommendationdone
April 2006 Success
Truvada and HIV Prevention: The Hope Behind the Hypedone
Big Expectations for Gene Therapydone
Development of NRTI Reverset Halteddone
February 2006 Success
Preventing HIV Transmission with Tenofovir + Emtricitabinedone
Investigating Reports of Excessive False-Positive Oral Fluid Rapid HIV Testsdone
Trends in HIV Diagnosis among Non-Hispanic Blacksdone
SMART and Treatment Interruptions: The Results Are Indone
May 2009 Success
Transcript: Antiretroviral Highlights from CROIdone
Transcript: HIV and Womendone
Transcript: HIV and the Braindone
Transcript: HIV and Cancer - Prevalence and Preventiondone
April 2009 Success
Transcript: Prevention Highlights Part 1- PrEPdone
Transcript: Prevention Highlights Part 2 - Treatment as Preventiondone
March 2009 Success
HIV and Womendone
February 2009 Success
Coming Soondone
Diabetes Drug Avandia Helps Reverse Lipoatrophydone
GS 9350 and SPI-452: Emerging Alternatives to Norvir Boostingdone
HIV Treatment Greatly Reduces, But Doesn’t Eliminate Transmissiondone
Kaletra-to-Isentress Switch Helps Lipids, but With Viral Rebound Riskdone
Start HIV Treatment Early—But When?done
IL-2 Fails in Two Large Studiesdone
Age, Diabetes & a Bigger Waist Line Tied to Cognitive Problems in HIVdone
PIs, Abacavir and Cardiovascular Disease: What’s the Risk?done
D:A:D Study: Reduce Modifiable Risk Factors to Improve Survivaldone
HIV Itself Is a Major Heart Disease Risk Factordone
Isentress Shows Long-Term Benefits in Treatment-Experienced Patientsdone
First Data From Injectable PRO 140 Studydone
Antidepressants Improve Viral Load Response to Treatment Due to Better Adherencedone
Microbicides Make a Comebackdone
Smoking Cessation: Hispanics, Nicotine Patch Users Do Bestdone
Nerve Damage Is a Common Problem in People With HIVdone
HDL and Small HDL Particles Predict Cardio Problems in HIVdone
Scientists Still Seeking Clues to Abacavir Heart Attack Mysterydone
Quarter of U.S. Positive Women Not Receiving Annual Pap Smearsdone
Aging and HIV a Destructive Combination on the Braindone
Antiretroviral Highlights from CROIdone
Testosterone Therapy: Good for Women Toodone
Lymphoma: Death Rates Still High, but Cancer May Be Predicteddone
Sexually Transmitted Hepatitis C in MSM in the U.S. and Europedone
Half of Deaths in People With HIV No Longer From AIDSdone
HIV and Cancer: Prevalence and Preventiondone
HIV and the Brain: What to Watch Out Fordone
Prevention Highlights, Part 1: PrEPdone
Prevention Highlights, Part 2: Treatment as Preventiondone
November 2008 Success
Truvada vs. Epzicom: The Debate Goes Ondone
Drug-Resistant Staph: Growing Concern Among People With HIVdone
High Number of Pulmonary Hypertension Cases in Naval HIV Cohort Studydone
Drug-Resistant Staph and HIV - Part 1done
Drug-Resistant Staph and HIV - Part 2done
HIV News at ICAAC/IDSA - Part 1done
HIV News at ICAAC/IDSA - Part 2done
October 2008 Success
Isentress Comparable to Sustiva for First-Time Treatmentdone
Selzentry Reanalysis Shows Potential as First-Line Treatmentdone
Should ARV Treatment Be Started When CD4s Fall Below 500?done
PRO 140 Has Long-Lasting Activity Against HIVdone
Greater HIV Response to Prezista vs. Kaletra for First-Timers Over 96 Weeksdone
New NNRTI Called RDEA806 Shows Promisedone
Higher Response Rate with Norvir-Boosted Reyataz vs. Kaletra as First-Line Therapydone
Has HIV Evolved to Become More Dangerous?done
Long-Term Benefits and Risks of Kaletra Monotherapy Explored in Two Studiesdone
IAC 2008 Success
Similar Survival Among IDUs on ARV Treatmentdone
Human Rights Struggles Define AIDS Fightdone
IAC Panelists: Scale Up, Leadership and Youth Crucial to HIV Responsedone
Future Options for the Treatment Experiencedin progress
Vaccines: Lessons Learnedwaiting
Abacavir and Heart Attack Risk: Round 2waiting
Achieving Universal Treatment Access: The Experience in Rural Malawiwaiting
Defining the Risk Factors for Kidney Damage in Patients Using Tenofovirwaiting
Sustiva Bests Kaletra for Treatment of Advanced HIV Diseasewaiting
Microbicides: Assessing Progresswaiting
IDX899 Safe, Reduces Viral Load in Preliminary Studywaiting
New Options for Those New to Treatmentwaiting
New HIV Numbers: New Prevention Strategy? Part 2waiting
AIDS Activism For The Next Decadewaiting
Hep C: The Other Epidemicwaiting
Some Gender and Racial Differences with Three Protease Inhibitorswaiting
PrEP: Preparing For Success?waiting
NNRTI Rilpivirine (TMC-278) Comparable to Sustiva in 96-Week Studywaiting
Encouraging Data From Second Tesamorelin Study for Lipowaiting
New HIV Numbers: New Prevention Strategy? Part 1waiting
Shortage of Health Care Workers Threatens African HIV Carewaiting
New NNRTI RDEA806 Shows Promise in Seven-Day Studywaiting
Transcript: AIDS Activism For The Next Decadewaiting
Transcript: Vaccines, Lessons Learnedwaiting
Studies Disagree on Abacavir for Patients With High Viral Loadswaiting
Abacavir and Cardiovascular Risk: Is There or Isn’t There?waiting
Isentress, Intelence and Prezista Combo Shines for Treatment Veteranswaiting
Transcript: Human Rights Struggles Define AIDS Fightwaiting
Having Children a Priority for Many Positive Womenwaiting
Milk Thistle Shows Potential for Hep Cwaiting
Transcript: Future Options for the Treatment Experiencedwaiting
Stigma, Fear of Side Effects, Keep Many off Treatmentwaiting
Report: Now Is Time to Prepare for PrEPwaiting
Norvir Tablets Similar to Capsules, Expected in 2009waiting
Transcript: PrEP - Preparing for Success?waiting
Annual HIV Infections in U.S. Substantially Higher Than Believedwaiting
Isentress Continues to Show Well Versus Sustiva as First-Line Treatmentwaiting
CROI 2008 waiting
December 2007 waiting
November 2007 waiting
October 2007 waiting
October 2007 waiting
September 2007 waiting
June 2009 waiting
May 2009 waiting
April 2009 waiting
March 2009 waiting
February 2009 waiting
January 2009 waiting
December 2008 waiting
November 2008 waiting
October 2008 waiting
September 2008 waiting
August 2008 waiting
July 2008 waiting
June 2008 waiting
May 2008 waiting
April 2008 waiting
March 2008 waiting
February 2008 waiting
January 2008 waiting
December 2007 waiting
November 2007 waiting
October 2007 waiting
September 2007 waiting
August 2007 waiting
July 2007 waiting
October 2007 waiting
August 2007 waiting
July 2007 waiting
CROI 2007 waiting
October 2005 waiting
Back to home » Top Stories » IAC 2008
IAC 2008 XVII International AIDS Conference
Mexico City, Mexico
August 3-8, 2008

Future Options for the Treatment Experienced

August 12, 2008

At the XVII International AIDS Conference in Mexico City, David Evans talks with Andrew Carr, MD, Professor of Medicine at the University of New South Wales in Sydney, Australia, who shares his views on the future of HIV treatment and what's in the pipeline for people with HIV who've been on many treatment regimens.

 

9 1/4 minutes. Click here to view the transcript.

Scroll down to comment on this story.

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 1 (of 1 total)    

mark, , 2008-08-13 12:48:10
the transcript is so much more important...

comments 1 - 1 (of 1 total)    

Our general International AIDS Conference coverage is made possible with a charitable grant from Bristol-Myers Squibb.

More from IAC 2008

Starting and Switching Treatment

August 12, 2008
Isentress, Intelence and Prezista Combo Shines for Treatment Veterans
Studies Disagree on Abacavir for Patients With High Viral Loads
August 6, 2008
Isentress Continues to Show Well Versus Sustiva as First-Line Treatment
Stigma, Fear of Side Effects, Keep Many off Treatment
Sustiva Bests Kaletra for Treatment of Advanced HIV Disease
August 5, 2008
Some Gender and Racial Differences with Three Protease Inhibitors
August 4, 2008
Similar Survival Among IDUs on ARV Treatment

HIV/AIDS Complications

August 15, 2008
Milk Thistle Shows Potential for Hep C
August 14, 2008
Defining the Risk Factors for Kidney Damage in Patients Using Tenofovir
August 13, 2008
Encouraging Data From Second Tesamorelin Study for Lipo
August 11, 2008
Abacavir and Cardiovascular Risk: Is There or Isn’t There?
August 7, 2008
Abacavir and Heart Attack Risk: Round 2
August 6, 2008
Hep C: The Other Epidemic

Experimental HIV Drugs

August 15, 2008
Norvir Tablets Similar to Capsules, Expected in 2009
August 12, 2008
Future Options for the Treatment Experienced
New Options for Those New to Treatment
August 11, 2008
IDX899 Safe, Reduces Viral Load in Preliminary Study
August 8, 2008
New NNRTI RDEA806 Shows Promise in Seven-Day Study
August 6, 2008
NNRTI Rilpivirine (TMC-278) Comparable to Sustiva in 96-Week Study

HIV Transmission and Prevention

August 18, 2008
Vaccines: Lessons Learned
August 15, 2008
PrEP: Preparing For Success?
August 14, 2008
New HIV Numbers: New Prevention Strategy? Part 1
New HIV Numbers: New Prevention Strategy? Part 2
August 7, 2008
Microbicides: Assessing Progress
Having Children a Priority for Many Positive Women
August 5, 2008
Report: Now Is Time to Prepare for PrEP
August 3, 2008
Annual HIV Infections in U.S. Substantially Higher Than Believed

Global HIV/AIDS

August 19, 2008
AIDS Activism For The Next Decade
August 15, 2008
Human Rights Struggles Define AIDS Fight
August 8, 2008
Achieving Universal Treatment Access: The Experience in Rural Malawi
August 6, 2008
Stigma, Fear of Side Effects, Keep Many off Treatment
August 4, 2008
Shortage of Health Care Workers Threatens African HIV Care
IAC Panelists: Scale Up, Leadership and Youth Crucial to HIV Response

Regan's Blog

August 6, 2008
La Voz Global
August 4, 2008
Bienvenidos a AIDS 2008!


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]

© 2009 Smart + Strong. All Rights Reserved. terms of use and your privacy